Vinorelbine Oral Plus Capecitabine Combination In Metastatic Breast Cancer
This study will evaluate the toxicity and secondary the efficacy of the combination vinorelbine plus capecitabine in metastatic breast cancer patients
Metastatic Breast Cancer
DRUG: Vinorelbine oral|DRUG: Capecitabine
Maximum Tolerated Dose (MTD) of vinorelbine oral plus capecitabine combination, Toxicity assessment at 1st cycle|Dose Limited Toxicity (DLT) of vinorelbine oral plus capecitabine combination., Toxicity assessment at 1st cycle
Response Rate, Response evaluation at 3rd and 6th cycle by CT's or MRI
The combination capecitabine-vinorelbine, with iv administration of vinorelbine, has been studied in a phase \[I\]/\[II\], with favourable profile of toxicity in pretreated patients with anthracyclines and/or taxanes (Oncology News International vol 12, no 3, suppl 2, 2003).

In a study of toxicity and effectiveness, Vanhopher reported objective response rates (PR) in 21 from 45 patients (47%) and stabilization of disease (SD) in 16 patients (36%). Severe leucopenia (grade 4), was reported in 5% of patients (Borquez D, et al: Proc Am Soc Clin Oncol 19: Abstract 420, 2000)